Literature DB >> 25820389

NLRC5 Mediates IL-6 and IL-1β Secretion in LX-2 Cells and Modulated by the NF-κB/Smad3 Pathway.

Tao Xu1, Ming-ming Ni, Cheng Huang, Xiao-ming Meng, Ying-hua He, Lei Zhang, Jun Li.   

Abstract

Recent data have shown that nucleotide-binding domain leucine-rich repeat proteins (NLRs), a class of innate immune receptors that respond to pathogen attack or cellular stress, have gained increasing attention. NLRC5 (NLR family, CARD domain containing 5) is the largest member of the NLR family, which has recently been identified as a critical regulator of immune responses. Until recently, the function of NLRC5 has been a matter of debate. In this study, we explore the role of NLRC5 in cytokine secretion and the role of the nuclear factor-κB (NF-κB) signaling pathway in tumor necrosis factor-alpha (TNF-α)-induced NLRC5 expression in LX-2 cells. We demonstrated that overexpression of NLRC5 results in an upregulation of IL-6 and IL-1β secretion. On the other hand, knockdown of NLRC5 by transfecting siRNA decreased IL-6 and IL-1β secretion in LX-2 cells. Meanwhile, the results showed that pyrrolidine dithiocarbamate (PDTC) (a specific inhibitor of the NF-κB signaling pathway) inhibited NLRC5 expression and NLRC5 silencing could increase the expression levels of p65 in cell nucleus accompanied with upregulated phosphorylation of Smad3 protein levels in response to TNF-α. These results indicated that NLRC5 plays a significant role in TNF-α-enhanced cytokine (IL-6 and IL-1β) secretion of LX-2 cells and the NF-κB/Smad3 signal pathway is involved in its induction of expression.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25820389     DOI: 10.1007/s10753-015-0157-6

Source DB:  PubMed          Journal:  Inflammation        ISSN: 0360-3997            Impact factor:   4.092


  23 in total

Review 1.  Hepatic fibrosis--role of hepatic stellate cell activation.

Authors:  Rifaat Safadi; Scott L Friedman
Journal:  MedGenMed       Date:  2002-07-15

Review 2.  The inflammasomes.

Authors:  Kate Schroder; Jurg Tschopp
Journal:  Cell       Date:  2010-03-19       Impact factor: 41.582

Review 3.  Anti-fibrogenic strategies and the regression of fibrosis.

Authors:  Tatiana Kisseleva; David A Brenner
Journal:  Best Pract Res Clin Gastroenterol       Date:  2011-04       Impact factor: 3.043

Review 4.  Molecular pathogenesis of hepatic fibrosis and current therapeutic approaches.

Authors:  Elisabetta Mormone; Joseph George; Natalia Nieto
Journal:  Chem Biol Interact       Date:  2011-07-22       Impact factor: 5.192

5.  Anti-fibrotic activity and enhanced interleukin-6 production by hepatic stellate cells in response to imatinib mesylate.

Authors:  Youngchul Kim; Maria I Fiel; Efsevia Albanis; Hsin I Chou; Weijia Zhang; Gregory Khitrov; Scott L Friedman
Journal:  Liver Int       Date:  2012-04-16       Impact factor: 5.828

6.  Anti-inflammatory activity of baicalein in LPS-stimulated RAW264.7 macrophages via estrogen receptor and NF-κB-dependent pathways.

Authors:  Guan-Wei Fan; Yuan Zhang; Xiaorui Jiang; Yan Zhu; Bingyao Wang; Lina Su; Wenjie Cao; Han Zhang; Xiumei Gao
Journal:  Inflammation       Date:  2013-12       Impact factor: 4.092

Review 7.  The microbial and danger signals that activate Nod-like receptors.

Authors:  Szilvia Benko; Dana J Philpott; Stephen E Girardin
Journal:  Cytokine       Date:  2008-08-19       Impact factor: 3.861

8.  Assessment of proteolytic degradation of the basement membrane: a fragment of type IV collagen as a biochemical marker for liver fibrosis.

Authors:  Sanne S Veidal; Morten A Karsdal; Arkadiusz Nawrocki; Martin R Larsen; Yueqin Dai; Qinlong Zheng; Per Hägglund; Ben Vainer; Helene Skjøt-Arkil; Diana J Leeming
Journal:  Fibrogenesis Tissue Repair       Date:  2011-10-05

9.  A NOD to zebrafish models of inflammatory bowel disease pathogenesis.

Authors:  Irving C Allen
Journal:  Dis Model Mech       Date:  2011-11       Impact factor: 5.758

10.  NLRC5 knockdown in chicken macrophages alters response to LPS and poly (I:C) stimulation.

Authors:  Ling Lian; Ceren Ciraci; Guobin Chang; Jingdong Hu; Susan J Lamont
Journal:  BMC Vet Res       Date:  2012-03-08       Impact factor: 2.741

View more
  7 in total

Review 1.  NLRC5: new cancer buster?

Authors:  Feng Tang; Yadi Xu; Bing Zhao
Journal:  Mol Biol Rep       Date:  2020-01-10       Impact factor: 2.316

2.  Negative immune factors might predominate local tumor immune status and promote carcinogenesis in cervical carcinoma.

Authors:  Minyi Zhao; Yang Li; Xing Wei; Qian Zhang; Hongran Jia; Shimin Quan; Di Cao; Li Wang; Ting Yang; Juan Zhao; Meili Pei; Sijuan Tian; Yang Yu; Yanping Guo; Xiaofeng Yang
Journal:  Virol J       Date:  2017-01-13       Impact factor: 4.099

3.  Alpha-Lipoic Acid Downregulates IL-1β and IL-6 by DNA Hypermethylation in SK-N-BE Neuroblastoma Cells.

Authors:  Simona Dinicola; Sara Proietti; Alessandra Cucina; Mariano Bizzarri; Andrea Fuso
Journal:  Antioxidants (Basel)       Date:  2017-09-26

Review 4.  NLRC5 Functions beyond MHC I Regulation-What Do We Know So Far?

Authors:  Szilvia Benkő; Elek Gergő Kovács; Felix Hezel; Thomas A Kufer
Journal:  Front Immunol       Date:  2017-02-17       Impact factor: 7.561

5.  NLRC5 promotes cell migration and invasion by activating the PI3K/AKT signaling pathway in endometrial cancer.

Authors:  Yijun Fan; Zhen Dong; Yuchuan Shi; Shiying Sun; Bing Wei; Lei Zhan
Journal:  J Int Med Res       Date:  2020-05       Impact factor: 1.671

6.  NLRC5 Serves as a Pro-viral Factor During Influenza Virus Infection in Chicken Macrophages.

Authors:  Shubhada K Chothe; Ruth H Nissly; Levina Lim; Gitanjali Bhushan; Ian Bird; Jessica Radzio-Basu; Bhushan M Jayarao; Suresh V Kuchipudi
Journal:  Front Cell Infect Microbiol       Date:  2020-05-19       Impact factor: 5.293

7.  NLRC5 Deficiency Deregulates Hepatic Inflammatory Response but Does Not Aggravate Carbon Tetrachloride-Induced Liver Fibrosis.

Authors:  Akouavi Julite I Quenum; Akhil Shukla; Fjolla Rexhepi; Maryse Cloutier; Amit Ghosh; Thomas A Kufer; Sheela Ramanathan; Subburaj Ilangumaran
Journal:  Front Immunol       Date:  2021-10-12       Impact factor: 7.561

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.